2001
Naltrexone in the Treatment of Alcohol Dependence
Krystal J, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the Treatment of Alcohol Dependence. New England Journal Of Medicine 2001, 345: 1734-1739. PMID: 11742047, DOI: 10.1056/nejmoa011127.Peer-Reviewed Original ResearchConceptsMonths of placeboSevere alcohol dependenceAlcohol dependencePlacebo-controlled evaluationUse of naltrexoneOpiate receptor antagonistTreatment of menSignificant differencesPercentage of daysStudy medicationNaltrexone groupPlacebo groupNumber of drinksAlcoholics Anonymous meetingsPsychosocial treatmentsNaltrexoneDrug AdministrationPatientsMonthsIndividual counselingNumber of daysPlaceboTreatmentWeeksDaysUse of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatientsNational Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology
Schneider L, Tariot P, Lyketsos C, Dagerman K, Davis K, Davis S, Hsiao J, Jeste D, Katz I, Olin J, Pollock B, Rabins P, Rosenheck R, Small G, Lebowitz B, Lieberman J. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal Of Geriatric Psychiatry 2001, 9: 346-360. PMID: 11739062, DOI: 10.1097/00019442-200111000-00004.Peer-Reviewed Original ResearchPerceived Needs and Service Use of Spanish Speaking Monolingual Patients Followed at a Hispanic Clinic
Diaz E, Prigerson H, Desai R, Rosenheck R. Perceived Needs and Service Use of Spanish Speaking Monolingual Patients Followed at a Hispanic Clinic. Community Mental Health Journal 2001, 37: 335-346. PMID: 11482751, DOI: 10.1023/a:1017552608517.Peer-Reviewed Original ResearchMeSH KeywordsAdultCommunication BarriersCommunity Mental Health CentersConnecticutCross-Sectional StudiesCultural DiversityEducational StatusFemaleHealth Care SurveysHealth Services, IndigenousHispanic or LatinoHumansLanguageMaleMiddle AgedNeeds AssessmentPatient CompliancePsychotropic DrugsSurveys and QuestionnairesConceptsMonolingual patientsPhysical health care providersMental health centersHealth care providersClinic patientsHealth centersAdditional interventionsCare providersService useHealth needsSociodemographic characteristicsNon-HispanicsPatientsClinicPerceived NeedsHispanicsPersistent effectsLow levelsBetter accessGreat needMedicationsMore difficultyLanguage barriers
1999
Enhancing Medication Compliance for People with Serious Mental Illness
Cramer J, Rosenheck R. Enhancing Medication Compliance for People with Serious Mental Illness. The Journal Of Nervous And Mental Disease 1999, 187: 53-55. PMID: 9952254, DOI: 10.1097/00005053-199901000-00009.Peer-Reviewed Original Research
1998
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer J, Rosenheck R. Compliance With Medication Regimens for Mental and Physical Disorders. Psychiatric Services 1998, 49: 196-201. PMID: 9575004, DOI: 10.1176/ps.49.2.196.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsDrug MonitoringHealth StatusHumansMental DisordersPatient ComplianceTime FactorsConceptsMedication complianceCompliance rateMicroelectronic monitoringMedication regimensPhysical disordersPsychiatric treatmentMedication compliance ratesDiscontinuation of medicationMean compliance rateAntidepressant medicationPill countAntipsychotic medicationNonpsychiatric disordersPatient compliancePsychiatric disordersPatientsPsychiatric patientsClinician judgmentMedicationsDisordersRegimensLower ratesTreatmentReportPercent
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol